Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta

NCT07096193 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07096193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07096193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 31, 2025
Completion date
January 31, 2030
Enrollment
200 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis delta